CHANDAN

Chandan Healthcare Share Price

 

 

Start SIP in CHANDAN

Start SIP
Chandan Healthcare live price: ₹250. It opened at ₹247 vs previous close ₹243; intraday high/low: ₹250/₹243. The 50 & 200 DMA stand at ₹271.67/₹252.61.

Chandan Healthcare Performance

  • Low
  • ₹243
  • High
  • ₹250
  • 52 Week Low
  • ₹150
  • 52 Week High
  • ₹358
  • Open Price₹247
  • Previous Close₹243
  • Volume10,400
  • 50 DMA₹271.67
  • 100 DMA₹275.17
  • 200 DMA₹252.61

Investment Returns

  • Over 1 Month -8.04%
  • Over 3 Month -11.96%
  • Over 6 Month + 11.11%
  • Over 1 Year + 50.11%

Smart Investing Starts Here Start SIP with Chandan Healthcare for Steady Growth!

Invest Now

Chandan Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.6
  • PEG Ratio
  • -
  • Market Cap Cr
  • 611
  • P/B Ratio
  • 4.3
  • Average True Range
  • 11.94
  • EPS
  • 11.33
  • Dividend Yield
  • 0
  • MACD Signal
  • -6.14
  • RSI
  • 36.35
  • MFI
  • 36.08

Chandan Healthcare Financials

Chandan Healthcare Technicals

EMA & SMA

Current Price
₹250.00
+ 6.75 (2.77%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹260.23
  • 50 Day
  • ₹271.67
  • 100 Day
  • ₹275.17
  • 200 Day
  • ₹252.61

Resistance and Support

244.43 Pivot Speed
  • R3 258.77
  • R2 254.38
  • R1 248.82
  • S1 238.87
  • S2 234.48
  • S3 228.92

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Chandan Diagnostics is a leading healthcare provider with 50+ centers and 500 collection points across Uttar Pradesh, Uttarakhand, and Rajasthan. Offering 3,500+ tests across multiple specialties, it ensures high-quality diagnostics with ISO and NABL-certified labs, cutting-edge automation, and seamless digital access.

Chandan Healthcare Ltd has an operating revenue of Rs. 265.83 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 14% is healthy, ROE of 18% is exceptional. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 5 indicates it belongs to a strong industry group of Medical-Outpnt/Hm Care and a Master Score of B is close to being the best. Overall, the stock has some strength but we want to see some buyer interest and further fundamental performance to qualify as a growth stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Chandan Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-14 Quarterly Results
2025-11-14 Quarterly Results
2025-10-10 To consider Fund Raising
2025-05-27 Audited Results

Chandan Healthcare F&O

Chandan Healthcare Shareholding Pattern

49.47%
0%
39.93%
10.6%

About Chandan Healthcare

  • NSE Symbol
  • CHANDAN
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Amar Singh
  • ISIN
  • INE0B2N01016

Similar Stocks to Chandan Healthcare

Chandan Healthcare FAQs

Chandan Healthcare share price is ₹250 As on 18 March, 2026 | 13:46

The Market Cap of Chandan Healthcare is ₹611.3 Cr As on 18 March, 2026 | 13:46

The P/E ratio of Chandan Healthcare is 27.6 As on 18 March, 2026 | 13:46

The PB ratio of Chandan Healthcare is 4.3 As on 18 March, 2026 | 13:46

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23